title: Everolimus in metastatic renal cell carcinoma: preliminary experience from Chang Gung Memorial Hospital.
abstract: BACKGROUND
  Everolimus has been approved for second-line treatment of patients with metastatic renal cell carcinoma (mRCC) after failure of sorafenib or sunitinib. The purpose of this retrospective study was to assess the efficacy and safety of everolimus in Taiwanese patients with mRCC.
  
  
  METHODS
  Between March 2009 and August 2011, 24 mRCC patients treated with everolimus were analyzed. Prior to everolimus, each patient had received therapy with at least one vascular endothelial growth factor receptor-tyrosine kinase inhibitor. Progression-free survival (PFS) and overall survival (OS) were estimated according to the Kaplan-Meier method.
  
  
  RESULTS
  Fifteen patients (62.5%) achieved stable disease. The median PFS was 7.1 months (95% confidence interval, 3.6-10.5 months). The median OS was 20.7 months (95% confidence interval, 5.0-36.4 months). The most frequent non-hematologic adverse events with everolimus were mucositis, rash, epistaxis and pneumonitis.
  
  
  CONCLUSIONS
  Everolimus is an effective second-line treatment for Taiwanese patients with mRCC. The toxicity is tolerable and manageable.
authors.affiliation: Division of Hematology-Oncology, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan, Taiwan.
authors.forename: Wen-Kuan
authors.initials: WK
authors.lastname: Huang
authors.forename: Chuang-Chi
authors.initials: CC
authors.lastname: Liaw
authors.forename: See-Tong
authors.initials: ST
authors.lastname: Pang
authors.forename: Cheng-Keng
authors.initials: CK
authors.lastname: Chuang
authors.forename: Yang-Jen
authors.initials: YJ
authors.lastname: Chiang
authors.forename: Chun-Te
authors.initials: CT
authors.lastname: Wu
authors.forename: Ying-Hsu
authors.initials: YH
authors.lastname: Chang
authors.forename: Hung-Ming
authors.initials: HM
authors.lastname: Wang
authors.forename: Yung-Chang
authors.initials: YC
authors.lastname: Lin
authors.forename: Jia-Juan
authors.initials: JJ
authors.lastname: Hsieh
authors.forename: Li-Ying
authors.initials: LY
authors.lastname: Ou
authors.forename: Shih-I
authors.initials: SI
authors.lastname: Tsai
authors.forename: Chih-Hsun
authors.initials: CH
authors.lastname: Yang
authors.forename: Cheng-Ta
authors.initials: CT
authors.lastname: Yang
authors.forename: John Wen-Cheng
authors.initials: JW
authors.lastname: Chang
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D018572:Disease-Free Survival; D000068338:Everolimus; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D012189:Retrospective Studies; D020123:Sirolimus / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D000068338:Everolimus; D020123:Sirolimus